EyeCool Therapeutics Appoints Dr. Richard Lindstrom to Board
News related to:EyeCool Therapeutics · 1 min read
EyeCool Therapeutics, a clinical-stage medical device company, has announced the appointment of Dr. Richard Lindstrom to its Board of Directors. Dr. Lindstrom, a board-certified ophthalmologist and surgeon with extensive experience in corneal, cataract, refractive, and anterior-segment ophthalmology, brings a wealth of expertise to the company.
Dr. Lindstrom is the founder and attending surgeon emeritus of Minnesota Eye Consultants and an Adjunct Professor Emeritus in the Department of Ophthalmology at the University of Minnesota. Throughout his career, he has been involved in the clinical development, evaluation, and adoption of ophthalmic technologies, and has served in various leadership, advisory, and board roles within the field.
Dr. Lindstrom’s appointment is significant for EyeCool Therapeutics as it advances its investigational in-office cooling device, ETX-4143, for chronic ocular surface pain. The clinical work completed in Australia supports the scientific rationale for precision ocular cooling in this condition, and the company is now preparing to initiate its U.S. clinical program.
Dr. Lindstrom’s addition to the Board of Directors is a powerful signal of confidence in the company’s mission to advance precision ocular cooling as a potential new therapeutic category for chronic ocular surface pain. His guidance will be invaluable as the company prepares for its next stage of U.S. clinical development.
EyeCool Therapeutics is pioneering precision ocular cooling as a potential new therapeutic category for chronic ocular surface pain. The company is advancing ETX-4143, an investigational in-office cooling device designed to provide fast, lasting relief for patients suffering from chronic ocular surface pain.